NCT04738695|Completed
SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)
SCOPE
Loading search results
SCOPE
Sponsor study identifier
observational
3,008
1 country
1
Study Start
February 1, 2021
Actual (reported)Primary Completion
December 31, 2021
Actual (reported)Study Completion
December 31, 2022
Actual (reported)Assessment of the seroprevalence and sero-incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Nursing Home (NH) residents and staff in Belgium.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 25, 2021
Actual (reported)February 1, 2021
Actual (reported)February 4, 2021
Actual (reported)December 31, 2021
Actual (reported)December 31, 2022
Actual (reported)Change of seroprevalence of anti-SARS-CoV-2 antibodies among nursing home residents and staff in Belgium
Change of seroprevalence of anti-SARS-CoV-2 antibodies among Belgian nursing home residents and staff detected in their capillary blood by a point of care test during a period of 10 months.
"Month 0", "Month 2", "Month 4", "Month 6", "Month 8", "Month 10", "Month 13", "Month 16", "Month 19", "Month 22"
Change in SARS-CoV-2 seroconversion among nursing home residents and staff in Belgium
Change in SARS-CoV-2 seroconversion among Belgian nursing home residents and staff conducted by detecting specific SARS-CoV-2 IgG/IgM in their capillary blood by a point of care test at each of the study follow-up testing points.
"Month 0", "Month 2", "Month 4", "Month 6", "Month 8", "Month 10", "Month 13", "Month 16", "Month 19", "Month 22"
Assess the risk of getting symptomatically SARS-CoV-2 infected between the seropositive and seronegative group at baseline
10 months
Assess the proportion of deaths within 10 months between sero-positive and -negative participants at baseline visit for NH residents.
10 months
Assess the seroconversion time in the group of sero-negative participants at baseline visit in relation to observed risk factors such as care dependency scale (for NH residents),type of job assignment and flu vaccination (for staff)
10 months
Assess the duration of SARS-CoV-2 antigen specific seropositivity among NH residents and staff in Belgium.
10 months
Assess the time until death within 10 months between sero-positive and -negative participants at baseline visit for NH residents
10 months
Follow-up of seroprevalence
Bimonthly finger pricks with collection of 1-10 drops of capillary blood for detection of anti-SARS-CoV-2 immune markers
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Nursing Home residents and staff members.
Ghent University
Ghent, Oost-Vlaanderen, 9000, Belgium
Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed. N Engl J Med. 2020 Mar 26;382(13):1194-1196. doi: 10.1056/NEJMp2002125. Epub 2020 Feb 19. No abstract available.
Meyers E, De Rop L, Deschepper E, Duysburgh E, De Burghgraeve T, Van Ngoc P, Digregorio M, Coen A, De Clercq N, Wallaert S, Buret L, Coenen S, De Sutter A, Scholtes B, Verbakel JY, Cools P, Heytens S. SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021. Vaccine. 2025 Apr 2;51:126865. doi: 10.1016/j.vaccine.2025.126865. Epub 2025 Feb 20.
Capillary blood (whole blood) samples: * collection using point-of-care rapid SARS-CoV-2 antibody test * collection on Dry Blood Spot saver card
An De Sutter, Prof. Dr.
University Ghent
3,008 participants (actual enrollment reported by the registry).
First Submitted
January 25, 2021
First Posted
February 4, 2021
Study Start
February 1, 2021
Actual (reported)Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members
Contact the study team to confirm eligibility.
Meyers E, De Rop L, Deschepper E, Duysburgh E, De Burghgraeve T, Van Ngoc P, Digregorio M, Delogne S, Coen A, De Clercq N, Buret L, Coenen S, De Sutter A, Scholtes B, Verbakel JY, Cools P, Heytens S. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. Eur J Gen Pract. 2023 Dec;29(2):2149732. doi: 10.1080/13814788.2022.2149732. Epub 2022 Nov 28.
Primary Completion
December 31, 2021
Actual (reported)Study Completion
December 31, 2022
Actual (reported)Last Updated
November 24, 2023
Record last verified: 2023-11
Data will be available on request.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: